Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 8, 2015, Pages 1805-1814

  Ye, Yumei ^a   Birnbaum, Gilad D ^b   Perez Polo, Jose R ^a   Nanhwan, Manjyot K ^a   Nylander, Sven ^c   Birnbaum, Yochai ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

adenosine; aspirin; platelet inhibitors; prostaglandin endoperoxide synthases; reperfusion injury

Indexed keywords

15 EPI LIPOXIN A4; ADENOSINE; CLOPIDOGREL; COLLAGEN TYPE 3; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 2; ICOSANOID; INTERLEUKIN 18; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; TICAGRELOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART MUSCLE REPERFUSION; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; THROMBOCYTE AGGREGATION INHIBITION; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FIBROSIS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE REMODELING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TIME;

ADENOSINE; ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; INJECTIONS, INTRAPERITONEAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TICLOPIDINE; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84938074255     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305655     Document Type: Article

References (55)

1. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 141 2 Suppl e89S 119S. doi: 10.1378/chest.11-2293
2. Hamm CW, Bassand JP, Agewall S, ESC Committee for Practice Guidelines ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011 32 2999 3054. doi: 10.1093/eurheartj/ehr236
3. Jneid H, Anderson JL, Wright RS, 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College Of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012 126 875 910
4. Steg PG, James SK, Atar D, ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012 33 2569 2619
5. Thygesen K, Alpert JS, Jaffe AS, Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons; Biomarker Subcommittee; ECG Subcommittee; Imaging Subcommittee; Classification Subcommittee; Intervention Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; ESC Committee for Practice Guidelines (CPG); Document Reviewers Third universal definition of myocardial infarction. J Am Coll Cardiol 2012 60 1581 1598. doi: 10.1016/j.jacc.2012.08.001
6. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 141 2 Suppl e637S e668S. doi: 10.1378/chest.11-2306
7. Wallentin L, Becker RC, Budaj A, PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 361 1045 1057. doi: 10.1056/NEJMoa0904327
8. Cannon CP, Harrington RA, James S, PLATelet inhibition and patient Outcomes Investigators Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010 375 283 293. doi: 10.1016/S0140-6736(09)62191-7
9. Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ., Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther 2014 19 209 219. doi: 10.1177/1074248413511693
10. Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R., Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014 63 872 877. doi: 10.1016/j.jacc.2013.09.067
11. van Giezen JJ, Sidaway J, Glaves P, Kirk I, Björkman JA., Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012 17 164 172. doi: 10.1177/1074248411410883
12. Cattaneo M, Schulz R, Nylander S., Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 2014 63 2503 2509. doi: 10.1016/j.jacc.2014.03.031
13. Kitakaze M, Minamino T, Node K, Takashima S, Funaya H, Kuzuya T, Hori M., Adenosine and cardioprotection in the diseased heart. Jpn Circ J 1999 63 231 243
14. Kloner RA., Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circ Res 2013 113 451 463. doi: 10.1161/CIRCRESAHA.112.300627
15. Nanhwan MK, Ling S, Kodakandla M, Nylander S, Ye Y, Birnbaum Y., Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol 2014 34 2078 2085. doi: 10.1161/ATVBAHA.114.304002
16. Montalescot G, van 't Hof AW., Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014 371 2339. doi: 10.1056/NEJMc1412729
17. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP., Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007 50 1852 1856. doi: 10.1016/j.jacc.2007.07.058
18. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB., Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999 34 1711 1720
19. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, AMISTAD-II Investigators A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005 45 1775 1780. doi: 10.1016/j.jacc.2005.02.061
20. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW., Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006 27 2400 2405. doi: 10.1093/eurheartj/ehl094
21. Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C, Ganame J, Dymarkowski S, Janssens S, Belmans A, Van de Werf F., High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J 2011 32 867 877. doi: 10.1093/eurheartj/ehq492
22. Fokkema ML, Vlaar PJ, Vogelzang M, Gu YL, Kampinga MA, de Smet BJ, Jessurun GA, Anthonio RL, van den Heuvel AF, Tan ES, Zijlstra F., Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv 2009 2 323 329. doi: 10.1161/CIRCINTERVENTIONS.109.858977.109.858977
23. Hausenloy DJ, Yellon DM., Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006 70 240 253. doi: 10.1016/j.cardiores.2006.01.017
24. Penna C, Mancardi D, Tullio F, Pagliaro P., Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol 2008 103 368 377. doi: 10.1007/s00395-007-0695-7
25. Kim SF, Huri DA, Snyder SH., Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005 310 1966 1970. doi: 10.1126/science.1119407
26. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, Huang MH, Uretsky BF, Perez-Polo JR, Birnbaum Y., Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 2006 290 H1960 H1968. doi: 10.1152/ajpheart.01137.2005
27. 12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther 2013 18 251 262. doi: 10.1177/1074248412467692
28. Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, Penn MS., Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost 2010 104 609 617. doi: 10.1160/TH09-12-0823
29. Patti G, Bárczi G, Orlic D, Mangiacapra F, Colonna G, Pasceri V, Barbato E, Merkely B, Edes I, Ostojic M, Wijns W, Di Sciascio G., Outcome comparison of 600-And 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol 2011 58 1592 1599. doi: 10.1016/j.jacc.2011.06.044
30. Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, Gibson CM., Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv 2013 6 671 683. doi: 10.1016/j.jcin.2013.03.014
31. Winter JL, Lindefjeld DS, Veas N, Guarda E, Valdebenito M, Méndez M, Pérez O, Zuanic K, Mestas M, Martínez A., Angiographic and electrocardiographic parameters of myocardial reperfusion in angioplasty of patients with ST elevation acute myocardial infarction loaded with ticagrelor or clopidogrel (MICAMI-TICLO trial). Cardiovasc Revasc Med 2014 15 284 288. doi: 10.1016/j.carrev.2014.07.001
32. Berthonneche C, Sulpice T, Boucher F, Gouraud L, de Leiris J, O'Connor SE, Herbert JM, Janiak P., New insights into the pathological role of TNF-Alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am J Physiol Heart Circ Physiol 2004 287 H340 H350. doi: 10.1152/ajpheart.01210.2003
33. Gurantz D, Cowling RT, Varki N, Frikovsky E, Moore CD, Greenberg BH., IL-1beta and TNF-Alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol 2005 38 505 515. doi: 10.1016/j.yjmcc.2004.12.015
34. Sandanger Ø Ranheim T, Vinge LE, The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res 2013 99 164 174. doi: 10.1093/cvr/cvt091
35. O'Brien LC, Mezzaroma E, Van Tassell BW, Marchetti C, Carbone S, Abbate A, Toldo S., Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol Med 2014 20 221 229. doi: 10.2119/molmed.2014.00034
36. LaFramboise WA, Bombach KL, Dhir RJ, Muha N, Cullen RF, Pogozelski AR, Turk D, George JD, Guthrie RD, Magovern JA., Molecular dynamics of the compensatory response to myocardial infarct. J Mol Cell Cardiol 2005 38 103 117. doi: 10.1016/j.yjmcc.2004.09.011
37. Liao Y, Lin L, Lu D, Fu Y, Bin J, Xu D, Kitakaze M., Activation of adenosine A1 receptor attenuates tumor necrosis factor-α induced hypertrophy of cardiomyocytes. Biomed Pharmacother 2011 65 491 495. doi: 10.1016/j.biopha.2011.06.008
38. Wagner DR, Combes A, McTiernan C, Sanders VJ, Lemster B, Feldman AM., Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-Alpha. Circ Res 1998 82 47 56
39. Hu S, Mao-Ying QL, Wang J, Wang ZF, Mi WL, Wang XW, Jiang JW, Huang YL, Wu GC, Wang YQ., Lipoxins and aspirin-Triggered lipoxin alleviate bone cancer pain in association with suppressing expression of spinal proinflammatory cytokines. J Neuroinflammation 2012 9 278. doi: 10.1186/1742-2094-9-278
40. Ariel A, Chiang N, Arita M, Petasis NA, Serhan CN., Aspirin-Triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-Alpha secretion from human T cells. J Immunol 2003 170 6266 6272
41. Hachicha M, Pouliot M, Petasis NA, Serhan CN., Lipoxin (LX)A4 and aspirin-Triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med 1999 189 1923 1930
42. Natarajan R, Salloum FN, Fisher BJ, Ownby ED, Kukreja RC, Fowler AA 3rd, Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol 2007 293 H1571 H1580. doi: 10.1152/ajpheart.00291.2007
43. Göser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Ottl R, Zittrich S, Blaudeck N, Hardt SE, Pfitzer G, Rose NR, Katus HA, Kaya Z., Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 2006 114 1693 1702. doi: 10.1161/CIRCULATIONAHA.106.635664
44. Manning JR, Carpenter G, Porter DR, House SL, Pietras DA, Doetschman T, Schultz Jel J., Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels. Growth Factors 2012 30 124 139. doi: 10.3109/08977194.2012.656759
45. Di Scipio F, Sprio AE, Folino A, Carere ME, Salamone P, Yang Z, Berrone M, Prat M, Losano G, Rastaldo R, Berta GN., Injured cardiomyocytes promote dental pulp mesenchymal stem cell homing. Biochim Biophys Acta 2014 1840 2152 2161. doi: 10.1016/j.bbagen.2014.03.005
46. Fathi E, Nassiri SM, Atyabi N, Ahmadi SH, Imani M, Farahzadi R, Rabbani S, Akhlaghpour S, Sahebjam M, Taheri M., Induction of angiogenesis via topical delivery of basic-fibroblast growth factor from polyvinyl alcohol-dextran blend hydrogel in an ovine model of acute myocardial infarction. J Tissue Eng Regen Med 2013 7 697 707. doi: 10.1002/term.1460
47. Zhao T, Zhao W, Chen Y, Ahokas RA, Sun Y., Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction. Int J Cardiol 2011 152 307 313. doi: 10.1016/j.ijcard.2010.07.024
48. Mewhort HE, Turnbull JD, Meijndert HC, Ngu JM, Fedak PW., Epicardial infarct repair with basic fibroblast growth factor-enhanced CorMatrix-ECM biomaterial attenuates postischemic cardiac remodeling. J Thorac Cardiovasc Surg 2014 147 1650 1659. doi: 10.1016/j.jtcvs.2013.08.005
49. Virag JA, Rolle ML, Reece J, Hardouin S, Feigl EO, Murry CE., Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol 2007 171 1431 1440. doi: 10.2353/ajpath.2007.070003
50. Yao HC, Liu T, Meng XY, Han QF, Zhang M, Wang LX., Effect of basic fibroblast growth factor on the myocardial expression of hypoxia-inducible factor-1α and vascular endothelial growth factor following acute myocardial infarction. Heart Lung Circ 2013 22 946 951. doi: 10.1016/j.hlc.2013.04.111
51. Ye Y, Lin Y, Perez-Polo R, Huang MH, Hughes MG, McAdoo DJ, Manickavasagam S, Uretsky BF, Birnbaum Y., Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol 2007 293 H813 H818. doi: 10.1152/ajpheart.00210.2007
52. Ye Y, Long B, Qian J, Perez-Polo JR, Birnbaum Y., Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin. Cardiovasc Drugs Ther 2010 24 391 399. doi: 10.1007/s10557-010-6252-x
53. Manickavasagam S, Ye Y, Lin Y, Perez-Polo RJ, Huang MH, Lui CY, Hughes MG, McAdoo DJ, Uretsky BF, Birnbaum Y., The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther 2007 21 321 330. doi: 10.1007/s10557-007-6036-0
54. Schrottmaier WC, Kral JB, Badrnya S, Assinger A., Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes. Thromb Haemost 2015 114. doi: 10.1160/TH14-11-0943
55. Hausenloy DJ, Baxter G, Bell R, Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol 2010 105 677 686. doi: 10.1007/s00395-010-0121-4